Vitamin D receptor (VDR) agonists emerge to retain pleiotropic anti-inflammatory properties, since they regulate innate and adaptive immunity by switching the immune response from proinflammatory T helper 1 (Th1) type to tolerogenic T helper 2 (Th2) type dominance.
This report contains market size and forecasts of Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist in global, including the following market information:
Global Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist Market Sales, 2017-2022, 2023-2028, (Kg)
Global top five Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist companies in 2021 (%)
The global Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Early-Stage Therapeutic Drugs Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist include Chugai Pharmaceutical, Hybrigenics, Lipidor, MC2 Therapeutics, OPKO Renal and Cerbios-Pharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (Kg)
Global Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist Market Segment Percentages, by Type, 2021 (%)
Early-Stage Therapeutic Drugs
Mid-Stage Therapeutic Drugs
Late-Stage Therapeutic Drugs
Global Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (Kg)
Global Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist Market Segment Percentages, by Application, 2021 (%)
Cancer
Cardiovascular Diseases
Kidney Diseases
Benign Prostatic Hyperplasia
Obesity Treatment
Others
Global Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (Kg)
Global Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist revenues share in global market, 2021 (%)
Key companies Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist sales in global market, 2017-2022 (Estimated), (Kg)
Key companies Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Chugai Pharmaceutical
Hybrigenics
Lipidor
MC2 Therapeutics
OPKO Renal
Cerbios-Pharma